These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
559 related articles for article (PubMed ID: 32052876)
41. [The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study]. Ishizaki M; Kaibori M; Matsui K; Yanagimoto Y; Nakatake R; Kwon AH Gan To Kagaku Ryoho; 2010 Nov; 37(12):2679-82. PubMed ID: 21224678 [TBL] [Abstract][Full Text] [Related]
43. Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy. Kim PH; Choi SH; Kim JH; Park SH Korean J Radiol; 2019 Mar; 20(3):385-398. PubMed ID: 30799569 [TBL] [Abstract][Full Text] [Related]
44. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618 [TBL] [Abstract][Full Text] [Related]
45. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article. Kang MK; Park JG; Lee HJ Medicine (Baltimore); 2018 Apr; 97(17):e0611. PubMed ID: 29703062 [TBL] [Abstract][Full Text] [Related]
46. Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review. Zhang W; Ouyang D; Huang Z; Che X Front Oncol; 2023; 13():1085166. PubMed ID: 36776344 [TBL] [Abstract][Full Text] [Related]
47. Does adjuvant hepatic artery infusion chemotherapy improve patient outcomes for hepatocellular carcinoma following liver resection? A meta-analysis. Hu L; Zheng Y; Lin J; Shi X; Wang A World J Surg Oncol; 2023 Apr; 21(1):121. PubMed ID: 37013589 [TBL] [Abstract][Full Text] [Related]
48. Significance of trans-hepatic arterial chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus. Akiyama M; Miyaaki H; Miuma S; Shibata H; Fujimoto M; Takeshita S; Ozawa E; Ichikawa T; Nakao K; Eguchi K Oncol Rep; 2008 Aug; 20(2):353-7. PubMed ID: 18636197 [TBL] [Abstract][Full Text] [Related]
49. Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report. Sano S; Nakata S; Wada S; Kuroiwa M; Sakai H; Kusama K; Machida T; Nishio A; Ito I; Sodeyama H World J Surg Oncol; 2019 Dec; 17(1):229. PubMed ID: 31878937 [TBL] [Abstract][Full Text] [Related]
50. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. Zhang X; Wang K; Wang M; Yang G; Ye X; Wu M; Cheng S Oncotarget; 2017 Apr; 8(17):29416-29427. PubMed ID: 28177886 [TBL] [Abstract][Full Text] [Related]
51. Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: A propensity score-matching cohort study. Chen S; Yuan B; Yu W; Wang X; He C; Chen C J Surg Oncol; 2022 Dec; 126(7):1205-1214. PubMed ID: 35856502 [TBL] [Abstract][Full Text] [Related]
52. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Tao ZW; Cheng BQ; Zhou T; Gao YJ Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):134-144. PubMed ID: 34955380 [TBL] [Abstract][Full Text] [Related]
53. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. Hatooka M; Kawaoka T; Aikata H; Inagaki Y; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Masaki K; Waki K; Kohno H; Kohno H; Moriya T; Nagaoki Y; Tamura T; Amano H; Katamura Y; Chayama K BMC Cancer; 2018 Jun; 18(1):633. PubMed ID: 29866075 [TBL] [Abstract][Full Text] [Related]
54. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345 [TBL] [Abstract][Full Text] [Related]
55. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. Wu J; Huang WJ; Wang HY; Wang YF; Peng BG; Zhou Q Med Oncol; 2015 Mar; 32(3):65. PubMed ID: 25691293 [TBL] [Abstract][Full Text] [Related]
56. Safety and efficacy of endovascular implantation of a portal vein stent combined with iodine-125 seed-strips followed by transcatheter arterial chemoembolization with sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis. Li S; Li L; Li B; Wang W Br J Radiol; 2020 Aug; 93(1112):20190279. PubMed ID: 32464068 [TBL] [Abstract][Full Text] [Related]
57. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. Masuda K; Ono A; Aikata H; Kawaoka T; Nelson Hayes C; Teraoka Y; Daijo K; Nakamura-Inagaki Y; Morio K; Fujino H; Kan H; Uchida T; Masaki K; Kobayashi T; Nakahara T; Makokha GN; Zhang Y; Nagaoki Y; Miki D; Tsuge M; Hiramatsu A; Imamura M; Abe-Chayama H; Kawakami Y; Ochi H; Chayama K J Gastroenterol; 2018 Jan; 53(1):107-118. PubMed ID: 28474222 [TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of sorafenib plus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Regmi P; Hu HJ; Lv TR; Paudyal A; Sah RB; Ma WJ; Jin YW; Li FY Surg Oncol; 2021 Dec; 39():101663. PubMed ID: 34583091 [TBL] [Abstract][Full Text] [Related]
59. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Fujino H; Kimura T; Aikata H; Miyaki D; Kawaoka T; Kan H; Fukuhara T; Kobayashi T; Naeshiro N; Honda Y; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Hyogo H; Takahashi S; Yoshimatsu R; Yamagami T; Kenjo M; Nagata Y; Awai K; Chayama K Hepatol Res; 2015 Jun; 45(6):607-17. PubMed ID: 25052365 [TBL] [Abstract][Full Text] [Related]
60. Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: A meta-analysis. Long GB; Xiao CW; Zhao XY; Zhang J; Li X Medicine (Baltimore); 2020 Jun; 99(26):e20745. PubMed ID: 32590750 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]